AB-MECA

• CAT Number: I001909
• CAS Number: 152918-26-8
• Molecular Formula: C18H21N7O4
• Molecular Weight: 399.40
• Purity: ≥95%
• Synonyms: (2S,3S,4R,5R)-5-[6-[(4-aminophenyl)methylamino]purin-9-yl]-3,4-dihydroxy-N-methyloxolane-2-carboxamide
• InChI: InChI=1S/C18H21N7O4/c1-20-17(28)14-12(26)13(27)18(29-14)25-8-24-11-15(22-7-23-16(11)25)21-6-9-2-4-10(19)5-3-9/h2-5,7-8,12-14,18,26-27H,6,19H2,1H3,(H,20,28)(H,21,22,23)/t12-,13+,14-,18+/m0/s1
• InChIKey: LDYMCRRFCMRFKB-MOROJQBDSA-N
• SMILES: CNC(=O)C1C(C(C(O1)N2C=NC3=C(N=CN=C32)NCC4=CC=C(C=C4)N)O)O

AB-MECA is a high affinity A3 adenosine receptor agonist with a binding Ki of 430.5 nM for human A3 receptors in CHO cells. AB-MECA can enhance plasma histamine level[1][2][3][4].
AB-MECA (1, 10, 100 μM; 24 hours) shows dose-dependent cytotoxicity in human lung cancer cell line A549[2].
[125I]AB-MECA has KD values for binding to A3 receptors in transfected CHO cells and in RBL-2H3 cells are 1.48 and 3.61 nM, respectively[3].
AB-MECA (3 ug/kg; iv) enhances plasma histamine level in mouse[4].
AB-MECA (0.3 mg/kg; iv) enhances antigen-induced bronchoconstriction in male albino guinea pigs, weighing 180-220 g[5].

Reference

[1]. L Yates, et al. Radioligand binding and functional responses of ligands for human recombinant adenosine A(3) receptors. Auton Autacoid Pharmacol. 2006 Apr;26(2):191-200.
 [Content Brief]

[2]. Solanki, N. D., et al. In Vitro Evaluation Of Anti-Cancer Potential Of A3 Adenosine Receptor Agonist On A549 Human Lung Cancer Cell Line. Int J Pharm Pharm Sci ; 2019 Jun; 11(6): 106-108.

[3]. X D Ji, et al. A selective agonist affinity label for A3 adenosine receptors. Biochem Biophys Res Commun. 1994 Aug 30;203(1):570-6.
 [Content Brief]

[4]. Endre G Mikus, et al. Interaction of SSR161421, a novel specific adenosine A(3) receptor antagonist with adenosine A(3) receptor agonists both in vitro and in vivo. Eur J Pharmacol. 2013 Jan 15;699(1-3):62-6.
 [Content Brief]

[5]. Endre G Mikus, et al. Evaluation of SSR161421, a novel orally active adenosine A3 receptor antagonist on pharmacology models. Eur J Pharmacol. 2013 Jan 15;699(1-3):172-9.
 [Content Brief]